Analyst: New Lundbeck drugs are the bright spot of the report
The most recent quarterly financial report from Lundbeck points in the right direction in regards to traversing the dreaded patent cliff, according to an analyst.
by Stefan Singh Kailay
Practically all of Lundbeck’s products sold more than expected by analysts in Q2 2013, but it is especially the development in newly-launched products that catches the eye of Sydbank analyst, Søren Løntoft Hansen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
